List of Tables 6
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Kidney Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Kidney Cancer 13
Kidney Cancer Therapeutics under Development by Companies 15
Kidney Cancer Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 35
Comparative Analysis 35
Mid Clinical Stage Products 36
Comparative Analysis 36
Early Clinical Stage Products 37
Comparative Analysis 37
Discovery and Pre-Clinical Stage Products 38
Comparative Analysis 38
Kidney Cancer Therapeutics Products under Development by Companies 39
Kidney Cancer Therapeutics Products under Investigation by
Universities/Institutes 48
Companies Involved in Kidney Cancer Therapeutics Development 75
Bristol-Myers Squibb Company 75
Genzyme Corporation 76
Boehringer Ingelheim GmbH 77
F. Hoffmann-La Roche Ltd. 78
Kyowa Hakko Kirin Co., Ltd. 79
Amgen Inc. 80
AstraZeneca PLC 81
Eli Lilly and Company 82
GlaxoSmithKline plc 83
Seattle Genetics, Inc. 84
Genentech, Inc. 85
Merck & Co., Inc. 86
Emergent BioSolutions Inc. 87
Oxford BioMedica plc 88
Light Sciences Oncology, Inc. 89
Novartis AG 90
ImClone Systems Incorporated 91
Astellas Pharma Inc. 92
Eisai Co., Ltd. 93
Ono Pharmaceutical Co., Ltd. 94
OSI Pharmaceuticals, Inc. 95
Pfizer Inc. 96
Taiho Pharmaceutical Co., Ltd. 97
Exelixis, Inc. 98
Alfacell Corporation 99
Celgene Corporation 100
Bayer AG 101
MannKind Corporation 102
3SBio Inc. 103
EntreMed, Inc. 104
Celldex Therapeutics, Inc. 105
Active Biotech AB 106
AEterna Zentaris Inc. 107
AIDA Pharmaceuticals, Inc. 108
Lorus Therapeutics Inc 109
Bionomics Limited 110
Northwest Biotherapeutics, Inc. 111
Cleveland BioLabs, Inc. 112
Patrys Limited 113
Keryx Biopharmaceuticals, Inc. 114
ARQULE, INC 115
Allos Therapeutics, Inc 116
Flamel Technologies S.A. 117
Dendreon Corporation 118
Green Cross Corporation 119
MOLOGEN AG 120
OncoTherapy Science, Inc. 121
Threshold Pharmaceuticals, Inc. 122
Innate Pharma SA 123
Protox Therapeutics Inc. 124
Rexahn Pharmaceuticals, Inc. 125
Debiopharm Group 126
Antisense Pharma GmbH 127
Wilex AG 128
Philogen S.p.A. 129
Cadila Pharmaceuticals Ltd. 130
ERYtech Pharma 131
immatics biotechnologies GmbH 132
Curacyte AG 133
Argos Therapeutics, Inc. 134
Cytheris SA 135
Altor BioScience Corporation 136
AgrenVec, S.L. 137
Alethia Biotherapeutics Inc. 138
Gene Signal International SA. 139
MacroGenics, Inc. 140
Pivotal BioSciences, Inc. 141
Neotropix, Inc. 142
Jennerex Biotherapeutics, Inc. 143
Endocyte, Inc. 144
Advenchen Laboratories, LLC 145
Immutep S.A. 146
Syndax Pharmaceuticals, Inc. 147
Esperance Pharmaceuticals, Inc. 148
Welichem Biotech Inc. 149
Tigris Pharmaceuticals, Inc. 150
AVEO Pharmaceuticals, Inc. 151
KAHR medical Ltd. 152
Advanced Cancer Therapeutics 153
Medical Enzymes AG 154
IkerChem S.L. 155
Immunovative Therapies, Ltd. 156
Kidney Cancer Therapeutics Assessment 157
Assessment by Monotherapy Products 157
Assessment by Combination Products 158
Assessment by Route of Administration 159
Assessment by Molecule Type 162
Drug Profiles 165
Nexavar - Drug Profile 165
Axitinib - Drug Profile 167
Axitinib - Drug Profile 169
Sutent - Drug Profile 171
ANYARA - Drug Profile 173
IMA901 - Drug Profile 174
TroVax - Drug Profile 175
NuLeusin - Drug Profile 177
Tivozanib - Drug Profile 178
Rencarex - Drug Profile 180
Dovitinib - Drug Profile 182
Aldesleukin for Kidney Cancer - Drug Profile 184
Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile 185
Bevacizumab + Torisel - Drug Profile 187
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 188
Interferon Alfa-2B + Bevacizumab - Drug Profile 189
Interferon Alfa-2B - Drug Profile 190
BAY43-9006 - Drug Profile 191
Sunitinib - Drug Profile 193
Dactinomycin + Doxorubicin + Vincristine - Drug Profile 194
Sorafenib Tosylate - Drug Profile 195
Recombinant Interferon Alfa + Isotretinoin - Drug Profile 196
Interferon Alfa + CCI-779 - Drug Profile 197
BCG Vaccine + Iressa - Drug Profile 198
Interleukin-2 - Drug Profile 199
Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride +
Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile 200
RAD001 - Drug Profile 203
TroVax + IL-2 - Drug Profile 205
Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile 207
Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 209
Interferon-Alpha - Drug Profile 211
Votrient - Drug Profile 212
Everolimus + Bevacizumab - Drug Profile 214
ANYARA + Interferon Alpha - Drug Profile 215
Sunitinib - Drug Profile 216
Interferon-alpha - Drug Profile 217
Interleukin 2 + Interferon-alpha2 - Drug Profile 218
Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile 219
Sorafenib - Drug Profile 220
Sorafenib + Sunitinib - Drug Profile 221
bevacizumab + recombinant interferon alfa - Drug Profile 222
Carboplatin + Methotrexate + Vinblastine - Drug Profile 223
aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile 225
Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride +
Etoposide + Vincristine Sulfate - Drug Profile 227
Doxorubicin hydrochloride - Drug Profile 230
Gemcitabine + Cisplatin - Drug Profile 231
Sunitinib - Drug Profile 233
Recombinant Gamma Interferon - Drug Profile 234
Cisplatin + Radiation Therapy - Drug Profile 235
Sunitinib - Drug Profile 236
Bevacizumab + Interferon Alfa-2a - Drug Profile 237
Kidney Cancer Therapeutics Drug Profile Updates 238
Kidney Cancer Therapeutics Discontinued Products 245
Kidney Cancer Therapeutics - Dormant Products 249
Kidney Cancer Product Development Milestones 270
Featured News & Press Releases 270
Appendix 279
Methodology 279
Expert Panel Validation 280
Contact Us 280
Disclaimer 280
List of Tables
Number of Products Under Development for Kidney Cancer, H1 2012 17
Products under Development for Kidney Cancer Comparative Analysis, H1 2012 18
Number of Products under Development by Companies, H1 2012 20
Number of Products under Development by Companies, H1 2012 (Contd..1) 21
Number of Products under Development by Companies, H1 2012 (Contd..2) 22
Number of Products under Development by Companies, H1 2012 (Contd..3) 23
Number of Products under Development by Companies, H1 2012 (Contd..4) 24
Number of Products under Development by Companies, H1 2012 (Contd..5) 25
Number of Products under Development by Companies, H1 2012 (Contd..6) 26
Number of Products under Investigation by Universities/Institutes, H1 2012 28
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..1) 29
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..2) 30
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..3) 31
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..4) 32
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..6) 34
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..7) 35
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..8) 36
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..9) 37
Number of Products under Investigation by Universities/Institutes, H1 2012
(Contd..10) 38
Comparative Analysis by Late Stage Development, H1 2012 39
Comparative Analysis by Mid Clinical Stage Development, H1 2012 40
Comparative Analysis by Early Clinical Stage Development, H1 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 42
Products under Development by Companies, H1 2012 43
Products under Development by Companies, H1 2012 (Contd..1) 44
Products under Development by Companies, H1 2012 (Contd..2) 45
Products under Development by Companies, H1 2012 (Contd..3) 46
Products under Development by Companies, H1 2012 (Contd..4) 47
Products under Development by Companies, H1 2012 (Contd..5) 48
Products under Development by Companies, H1 2012 (Contd..6) 49
Products under Development by Companies, H1 2012 (Contd..7) 50
Products under Development by Companies, H1 2012 (Contd..8) 51
Products under Investigation by Universities/Institutes, H1 2012 52
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 53
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 54
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 55
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 56
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 57
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 58
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 59
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 60
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 61
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 62
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 63
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 64
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 65
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 66
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 67
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 68
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 69
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 70
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 71
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 72
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 73
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 74
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 75
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 76
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 77
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 78
Bristol-Myers Squibb Company, H1 2012 79
Genzyme Corporation, H1 2012 80
Boehringer Ingelheim GmbH, H1 2012 81
F. Hoffmann-La Roche Ltd., H1 2012 82
Kyowa Hakko Kirin Co., Ltd., H1 2012 83
Amgen Inc., H1 2012 84
AstraZeneca PLC, H1 2012 85
Eli Lilly and Company, H1 2012 86
GlaxoSmithKline plc, H1 2012 87
Seattle Genetics, Inc., H1 2012 88
Genentech, Inc., H1 2012 89
Merck & Co., Inc., H1 2012 90
Emergent BioSolutions Inc., H1 2012 91
Oxford BioMedica plc, H1 2012 92
Light Sciences Oncology, Inc., H1 2012 93
Novartis AG, H1 2012 94
ImClone Systems Incorporated, H1 2012 95
Astellas Pharma Inc., H1 2012 96
Eisai Co., Ltd., H1 2012 97
Ono Pharmaceutical Co., Ltd., H1 2012 98
OSI Pharmaceuticals, Inc., H1 2012 99
Pfizer Inc., H1 2012 100
Taiho Pharmaceutical Co., Ltd., H1 2012 101
Exelixis, Inc., H1 2012 102
Alfacell Corporation, H1 2012 103
Celgene Corporation, H1 2012 104
Bayer AG, H1 2012 105
MannKind Corporation, H1 2012 106
3SBio Inc., H1 2012 107
EntreMed, Inc., H1 2012 108
Celldex Therapeutics, Inc., H1 2012 109
Active Biotech AB, H1 2012 110
AEterna Zentaris Inc., H1 2012 111
AIDA Pharmaceuticals, Inc., H1 2012 112
Lorus Therapeutics Inc, H1 2012 113
Bionomics Limited, H1 2012 114
Northwest Biotherapeutics, Inc., H1 2012 115
Cleveland BioLabs, Inc., H1 2012 116
Patrys Limited, H1 2012 117
Keryx Biopharmaceuticals, Inc., H1 2012 118
ARQULE, INC, H1 2012 119
Allos Therapeutics, Inc, H1 2012 120
Flamel Technologies S.A., H1 2012 121
Dendreon Corporation, H1 2012 122
Green Cross Corporation, H1 2012 123
MOLOGEN AG, H1 2012 124
OncoTherapy Science, Inc., H1 2012 125
Threshold Pharmaceuticals, Inc., H1 2012 126
Innate Pharma SA, H1 2012 127
Protox Therapeutics Inc., H1 2012 128
Rexahn Pharmaceuticals, Inc., H1 2012 129
Debiopharm Group, H1 2012 130
Antisense Pharma GmbH, H1 2012 131
Wilex AG, H1 2012 132
Philogen S.p.A., H1 2012 133
Cadila Pharmaceuticals Ltd., H1 2012 134
ERYtech Pharma, H1 2012 135
immatics biotechnologies GmbH, H1 2012 136
Curacyte AG, H1 2012 137
Argos Therapeutics, Inc., H1 2012 138
Cytheris SA, H1 2012 139
Altor BioScience Corporation, H1 2012 140
AgrenVec, S.L., H1 2012 141
Alethia Biotherapeutics Inc., H1 2012 142
Gene Signal International SA., H1 2012 143
MacroGenics, Inc., H1 2012 144
Pivotal BioSciences, Inc., H1 2012 145
Neotropix, Inc., H1 2012 146
Jennerex Biotherapeutics, Inc., H1 2012 147
Endocyte, Inc., H1 2012 148
Advenchen Laboratories, LLC, H1 2012 149
Immutep S.A., H1 2012 150
Syndax Pharmaceuticals, Inc., H1 2012 151
Esperance Pharmaceuticals, Inc., H1 2012 152
Welichem Biotech Inc., H1 2012 153
Tigris Pharmaceuticals, Inc., H1 2012 154
AVEO Pharmaceuticals, Inc., H1 2012 155
KAHR medical Ltd., H1 2012 156
Advanced Cancer Therapeutics, H1 2012 157
Medical Enzymes AG, H1 2012 158
IkerChem S.L., H1 2012 159
Immunovative Therapies, Ltd., H1 2012 160
Assessment by Monotherapy Products, H1 2012 161
Assessment by Combination Products, H1 2012 162
Assessment by Stage and Route of Administration, H1 2012 165
Assessment by Molecule Type, H1 2012 168
Kidney Cancer Therapeutics Drug Profile Updates 242
Kidney Cancer Therapeutics Discontinued Products 249
Kidney Cancer Therapeutics Discontinued Products (Contd..1) 250
Kidney Cancer Therapeutics Discontinued Products (Contd..2) 251
Kidney Cancer Therapeutics Discontinued Products (Contd..3) 252
Kidney Cancer Therapeutics Dormant Products 253
Kidney Cancer Therapeutics Dormant Products (Contd..1) 254
Kidney Cancer Therapeutics Dormant Products (Contd..2) 255
Kidney Cancer Therapeutics Dormant Products (Contd..3) 256
Kidney Cancer Therapeutics Dormant Products (Contd..4) 257
Kidney Cancer Therapeutics Dormant Products (Contd..5) 258
Kidney Cancer Therapeutics Dormant Products (Contd..6) 259
Kidney Cancer Therapeutics Dormant Products (Contd..7) 260
Kidney Cancer Therapeutics Dormant Products (Contd..8) 261
Kidney Cancer Therapeutics Dormant Products (Contd..9) 262
Kidney Cancer Therapeutics Dormant Products (Contd..10) 263
Kidney Cancer Therapeutics Dormant Products (Contd..11) 264
Kidney Cancer Therapeutics Dormant Products (Contd..12) 265
Kidney Cancer Therapeutics Dormant Products (Contd..13) 266
Kidney Cancer Therapeutics Dormant Products (Contd..14) 267
Kidney Cancer Therapeutics Dormant Products (Contd..15) 268
Kidney Cancer Therapeutics Dormant Products (Contd..16) 269
Kidney Cancer Therapeutics Dormant Products (Contd..17) 270
Kidney Cancer Therapeutics Dormant Products (Contd..18) 271
Kidney Cancer Therapeutics Dormant Products (Contd..19) 272
Kidney Cancer Therapeutics Dormant Products (Contd..20) 273
List of Figures
Number of Products under Development for Kidney Cancer, H1 2012 17
Products under Development for Kidney Cancer Comparative Analysis, H1 2012 18
Products under Development by Companies, H1 2012 19
Products under Investigation by Universities/Institutes, H1 2012 27
Late Stage Products, H1 2012 39
Mid Clinical Stage Products, H1 2012 40
Early Clinical Stage Products, H1 2012 41
Discovery and Pre-Clinical Stage Products, H1 2012 42
Assessment by Monotherapy Products, H1 2012 161
Assessment by Combination Products, H1 2012 162
Assessment by Route of Administration, H1 2012 163
Assessment by Stage and Route of Administration, H1 2012 164
Assessment by Molecule Type, H1 2012 166
Assessment by Stage and Molecule Type, H1 2012 167
|
